Tenofovir Disoproxil Fumarate Safety for Women and their Infants during Pregnancy and Breastfeeding: Systematic Review.
Mofenson LM, Baggaley RC, Mameletzis I. 
AIDS. 2016 Nov 7.
Abstract

Tenofovir exposure in utero and linear growth in HIV exposed, uninfected infants: a prospective study.
M le Roux S, Jao J, Brittain K, . et al
AIDS. 2016 Oct 14.
Abstract

Serum phosphate and creatinine levels in the first year of life in infants born to HIV-positive mothers receiving tenofovir-based combination regimens during pregnancy and prolonged breastfeeding in an option B+ programme in Malawi.
Floridia M, Liotta G, Andreotti M,  et al
J Acquir Immune Defic Syndr. 2016 Aug 24
Abstract

In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants.
Denneman L, Cohen S, Godfried MH,  et al
AIDS. 2016 Aug 24;30(13):2135-7
Abstract

FULL-TEXT ARTICLE
Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.
Jourdain G, Ngo-Giang-Huong N, Cressey TR,  et al
BMC Infect Dis. 2016 Aug 9;16:393.
Paper

Detectable tenofovir levels in breastfeeding infants of mothers exposed to topical tenofovir.
Noguchi LM, Montgomery ET, Biggio JR,
Antimicrob Agents Chemother. 2016 Jul 11.
Abstract

Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Palombi L, Pirillo MF, Marchei E, et al 
J Antimicrob Chemother. 2015 Dec 17.
Abstract

Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.
Wang J, Liu J, Qi C, Yan T, et al
Antivir Ther. 2015 Jul 28
Abstract

Lower Newborn Bone Mineral Content Associated with Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
Siberry GK, Jacobson DL, Kalkwarf HJ, et al
Clin Infect Dis. 2015 Jun 9. pii: civ437
Abstract

Pharmacokinetics of tenofovir during pregnancy and postpartum.
Best BM, Burchett S, Li H,  et al
HIV Med. 2015 May 11.
Abstract

Pharmacokinetics of Once versus Twice Daily Darunavir In Pregnant HIV-Infected Women.
Stek A, Best BM, Wang J,  et al
J Acquir Immune Defic Syndr. 2015 May 6
Abstract

FULL-TEXT PDF ARTICLE
Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Mansoor LE, Karim QA, Mngadi KT, et al
Trials. 2014 Dec 19;15(1):496.
Paper

Use of Tenofovir Disoproxil Fumarate in Highly Viremic, Hepatitis B Mono-Infected Pregnant Women.
Tsai PJ, Chang A, Yamada S, et al.
Dig Dis Sci. 2014 Jun 5.
Abstract

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of Hepatitis B Virus
Greenup AJ, Tan PK, Nguyen V,  et al
J Hepatol. 2014 May 3.
Abstract

Safety of tenofovir during pregnancy for the mother and fetus: A systematic review.
Wang L, Kourtis AP, Ellington S,et al
Clin Infect Dis. 2013 Sep 17.
Abstract

Pharmacokinetics and Safety of Tenofovir in HIV-infected Women during Labor and their Infants During the First Week of Life.
Mirochnick M, Taha T, Kreitchmann R,  et al
J Acquir Immune Defic Syndr. 2013 Aug 23
Abstract

Tenofovir useand pregnancy among women initiating HAART.
Maskew M, Westreich D, Firnhaber C, Sanne I.
AIDS. 2012 Aug 28
Abstract

FULL-TEXT ARTICLE
Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial.
Gibb DM, Kizito H, Russell EC,  et al
PLoS Med. 2012 May;9(5):e1001217
Paper

Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Siberry GK, Williams PL, Mendez H,  et al 
AIDS. 2012 Feb 29
Abstract